Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $64.86 Consensus Price Target from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTGet Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $64.86.

ARCT has been the subject of a number of analyst reports. Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Tuesday, July 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd.

Check Out Our Latest Research Report on ARCT

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $22.48 on Wednesday. The firm has a market cap of $605.39 million, a P/E ratio of -5.75 and a beta of 2.64. The firm has a 50 day simple moving average of $29.54 and a 200 day simple moving average of $32.25. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCTGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The business had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. On average, sell-side analysts expect that Arcturus Therapeutics will post -4.39 EPS for the current year.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the transaction, the chief operating officer now directly owns 447,448 shares of the company’s stock, valued at $17,902,394.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its position in Arcturus Therapeutics by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock valued at $64,564,000 after acquiring an additional 146,141 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Arcturus Therapeutics by 11.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after acquiring an additional 115,087 shares in the last quarter. FMR LLC lifted its position in Arcturus Therapeutics by 8.6% in the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock valued at $24,024,000 after acquiring an additional 74,081 shares in the last quarter. Granahan Investment Management LLC lifted its position in Arcturus Therapeutics by 12.9% in the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock valued at $14,200,000 after acquiring an additional 51,504 shares in the last quarter. Finally, Great Lakes Advisors LLC bought a new stake in Arcturus Therapeutics in the 4th quarter valued at $6,531,000. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Company Profile

(Get Free Report

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Read More

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.